Back to search results

Etonogestrel Implant as Emergency Contraception

This study is looking at whether the etonogestrel implant, a type of birth control, can prevent ovulation (the release of an egg) when inserted just before ovulation is expected. Researchers will insert the implant in women who have regular menstrual cycles and are between 18 and 40 years old, with a BMI (Body Mass Index) of 28 or less. They will measure hormone levels in your blood and check your ovaries with ultrasound to see if ovulation is stopped. The goal is to see if placing the implant at this specific time can work as emergency contraception. This study plans to enroll 12 participants, but its current status is unclear.

Study design
This is a single-site, single-arm, open-label pilot study, meaning all participants will receive the etonogestrel implant and everyone involved will know what treatment is being given. It plans to enroll 12 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your serum progesterone and ovarian follicle size will be measured at 7 days after the implant insertion.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05237141

Etonogestrel Implant as Emergency Contraception

Recruiting
PHASE4Ages 18–40InterventionalBasic science
University of Colorado, Denver
~12 participants
Updated 2026-08-11 on ClinicalTrials.gov
What's tested:Etonogestrel implant

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Serum progesterone
Measured over 7 days
+1 more outcome measured

Conditions

Contraception

Explore related trials

Contraception

Where it's being run

1 sites across 1 states
Colorado1

Who to contact

Emily Graves, BS
[email protected]
303-724-3514
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

BMI less than or equal to 28kg/m2
Intact uterus with at least one ovary
Regular menstrual cycles that occur every 21-35 days
If patient is postpartum or post-second trimester abortion, 3 menses (2 cycles) must have occurred prior to enrollment
If patient had a first trimester abortion or pregnancy loss, she must have one spontaneous menses prior to enrollment
Desires insertion of an etonogestrel contraceptive implant for contraception
Not currently pregnant or trying to become pregnant
Willing to abstain from medications and supplements known to induce/inhibit CYP3A4 during the study

Exclusion

Have a known hypersensitivity or contraindications to etonogestrel.
Medical conditions that affect liver function (e.g., hepatitis, cirrhosis; assessed via participant self-report)
Known or suspected current alcohol dependence syndrome or any illicit drug use that may affect the metabolism of the etonogestrel.
Uncontrolled thyroid disorder.
Use of long-acting injectable hormonal contraceptive within the past 9 months
Current use of hormonal oral, patch, intravaginal, or intrauterine contraception

What this trial measures

  • Serum progesterone7 days

    Serial measurements of serum progesterone will be conducted after insertion of the etonogestrel implant to assess for evidence of potential ovulation (\>3ng/mL)

  • Ovarian follicle size7 days

    Serial transvaginal ultrasound measurements of the leading or dominant follicle will be conducted after insertion of the etonogestrel implant. Ovulation will be defined by follicle rupture with complete disappearance or at least a 50% reduction in the mean size of the leading follicle.